Rise and shine, everyone, another busy day is on the way. Summertime may still be with us, but there is work to be done. To cope, yes, we are firing up the coffee kettle and downing a few cups of stimulation — we are still stuck on cinnamon dolce, for those tracking this sort of thing. Meanwhile, here are a few items of interest to help you with your own busy routine. We hope your day is productive and you conquer the world, such as it is. And of course, do keep safe. …
Sanofi (SNY) has drawn another blank in its attempt to repurpose its Kevzara rheumatoid arthritis drug to tackle the extreme immune reaction seen in serious cases of Covid-19, Pharmaphorum says. The drug failed to meet the main goals of a U.S. study testing it in the most critically ill Covid-19 patients. As a result, Sanofi and its partner, Regeneron Pharmaceuticals (REGN), do not anticipate conducting further clinical studies for Kevzara for combating the coronavirus.
AstraZeneca (AZN) has begun enrolling adults for a U.S.-funded, 30,000-subject late-stage study of its Covid-19 vaccine candidate, Reuters writes. Trial participants will receive either two doses of the experimental vaccine, dubbed AZD1222, four weeks apart, or a placebo. The trial is being conducted under the U.S. government’s Operation Warp Speed program, which aims to accelerate development, manufacturing, and distribution of vaccines and treatments for Covid-19.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect